Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here? Journal of Allergy and Clinical Immunology

T. Eiwegger, K. Anagnostou, S. Arasi, P. Bégin, M. Ben-Shoshan, K. Beyer, K. Blumchen, H. Brough, J.-C. Caubet, E.S. Chan, M. Chen, S. Chinthrajah, C.M. Davis, A. Des Roches, G. Du Toit, A. Elizur, S.J. Galli, G. Håland, K. Hoffmann-Sommergruber, H. KimD.Y.M. Leung, A. Long, A. Muraro, U.B. Nurmatov, G.B. Pajno, V. Sampath, J. Saxena, S. Sindher, J. Upton, M. Worm, K.C. Nadeau

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1153-1156
Number of pages4
JournalJ. Allergy Clin. Immunol.
Volume145
Issue number4
DOIs
Publication statusPublished - 2020

Keywords

  • efficacy
  • Food allergy
  • Institute for Clinical and Economic Review
  • management
  • peanut allergy
  • quality of life
  • safety
  • treatment
  • US Food and Drug Administration Allergenic Products Advisory Committee
  • Editorial
  • human
  • oral immunotherapy
  • peanut
  • priority journal
  • advisory committee
  • desensitization
  • Food and Drug Administration
  • government regulation
  • immunology
  • oral drug administration
  • organization
  • procedures
  • United States
  • Academies and Institutes
  • Administration, Oral
  • Advisory Committees
  • Desensitization, Immunologic
  • Government Regulation
  • Humans
  • Peanut Hypersensitivity
  • Policy Making
  • United States Food and Drug Administration

Cite this